Ranbaxy wins the Norwegian battle

IIPM PUBLICATION
In yet another patent case, the tables were turned in favour of Ranbaxy Laboratories Ltd. On August 30, the Oslo City Court in Norway ruled in favour of the company, stating that it did not infringe on Pfizer’s two Norwegian patents, which covered particular intermediate compounds. In November 2005, the Norwegian court had ruled that though Ranbaxy’s Atorvastatin did not infringe one of the process patents of Pfizer, but it violated another Pfizer patent. Ranbaxy can now introduce Atorvastatin in the Norwegian market. The low cholesterol drug, Atorvastatin is marketed as Lipitor by Pfizer.

For Complete IIPM Article, Click on IIPM Article

Source : IIPM Editorial, 2006, Arindam Chaudhuri's Initiative

For More IIPM Article, Visit Below......
Bajaj zooming down Indian roads
Back in action with all new plans
Rite Aid acquires to aid its drug stores
TomKat to the rescue!
IIPM Alliances
IIPM Academics : Global Outreach Program
GLOBAL OPPORTUNITY & THREAT ANALYSIS (GOTA)